Organisation
Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven)
Division
The Lab of Molecular Oncology and Angiogenesis aims to shed light on the genetic and molecular mechanisms that regulate vessel shape remodeling and endothelial cell fate, with the overall aim of defining alternative therapeutic opportunities to improve anti-cancer therapy, as well as therapeutic angiogenesis for revascularization of ischemic tissues.
Current researchers
1 - 7 of 7 results
- Max Mazzone (Responsible)
- Emanuele Berardi (Member)
- Marie-Pauline Orban (Member)
- Carla Riera Domingo (Member)
- Silvia Rivis (Member)
- Tommaso Scolaro (Member)
- Shikang Zhao (Member)
Projects
1 - 10 of 69
- Targeting the DNA methylation profile of cytotoxic T cells to overcome immunotherapy resistance of pancreatic cancerFrom5 Mar 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding glutamate metabolism in the tumor microenvironment to tackle Immune Checkpoint Blockade (ICB) resistanceFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Role of SLC1A3 in tumor-associated macrophages during immunotherapy resistance onset in breast cancerFrom1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Targeting the CDA/P2Y6 axis to overcome immunosuppression and favor response to immune checkpoint inhibitors in pancreatic cancerFrom1 Jul 2023 → TodayFunding: Other federal public and semi-governmental institutions
- Tackling tumor immunosuppression by reprograming eicosanoid metabolism and signaling in the tumor microenvironmentFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Understanding the roles of the epigenetic machinery in shaping distinct tumor-associated macrophage phenotypes.From10 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Tackling SLC1A3 in tumor-associated macrophages to overcome anti-PD1 immunotherapy resistance in breast cancerFrom31 Oct 2022 → TodayFunding: FWO Strategic Basic Research Grant
- LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- BD Imaging Cell Sorter – BD Cell View TechnologyTMFrom24 Jun 2022 → TodayFunding: Other federal scientific institutions
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
Publications
21 - 30 of 314
- Substrains of Inbred Mice Differ in Their Physical Activity as a Behavior(2013)
Authors: Emanuele Berardi
- Altering the intratumoral localization of macrophages to inhibit cancer progression(2014)
Authors: Andrea Casazza, Max Mazzone
- Novel Therapeutic Approaches for Skeletal Muscle Dystrophies(2015)
Authors: Emanuele Berardi, Maurilio Sampaolesi
Pages: 394 - 412 - Sublobar Resection Versus Lobectomy for Early-Stage Pulmonary Carcinoid Tumors ≤3 cm in Size A SEER Population-Based Study(2022)
Authors: Shikang Zhao
Pages: E991 - E999 - Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity(2012)
Authors: Sofie Deschoemaeker, Anne-Theres Henze, Koen Debackere, Veronica Finisguerra, Lorenzo Veschini, Myriam Baes, Jan D'hooge, Peter Carmeliet, Max Mazzone
Pages: 263 - 277 - Repression of hypoxia-inducible factor-1 contributes to increased mitochondrial reactive oxygen species production in diabetes(2022)
Authors: Max Mazzone, Peter Carmeliet
- Role of Dll4/Notch in the Formation and Wiring of the Lymphatic Network in Zebra Fish(2010)
Authors: Ilse Geudens, Frederik De Smet, Wouter Vandevelde, Filip Claes, Max Mazzone, Holger Gerhardt, Annelii Ny, Tobias Langenberg, Peter Carmeliet, Mieke Dewerchin
Pages: 1695 - 1702 - An early-senescence state in aged mesenchymal stromal cells contributes to hematopoietic stem and progenitor cell clonogenic impairment through the activation of a pro-inflammatory program(2019)
Authors: Daniela Gnani, Stefania Crippa, Lucrezia della Volpe, Valeria Rossella, Anastasia Conti, Emanuele Lettera, Silvia Rivis, Marco Ometti, Gianfranco Fraschini, Maria Ester Bernardo, et al.
- Mesenchymal stromal cells improve the transplantation outcome of CRISPR-Cas9 gene-edited HSPCs(2021)
Authors: Silvia Rivis
Pages: A57 - A57 - Mesenchymal stromal cells improve the transplantation outcome of CRISPR-Cas9 gene-edited human HSPCs (Aug, 10.1016/j.ymthe.2022.08.011, 2022)(2022)
Authors: Silvia Rivis
Pages: 3333 - 3333